Enteral Feeding Formulas Market

Enteral Feeding Formulas Market Overview

The Global Enteral Feeding Formula Market is expected to grow at 9.64 % CAGR from 2024 to 2033. It is expected to reach above USD 18.10 billion by 2033 from USD 9.10 billion in 2024.

Specialized nutritional solutions known as enteral feeding formulae are used by people who are unable to take enough food orally. They include vitamins, minerals, macronutrients, and other vital elements in a well-balanced mix. These formulations promote general health and wellbeing by being delivered into the gastrointestinal system via a feeding tube. Patients recuperating from surgery, disease, or trauma benefit most from them.

In order to prevent and cure malnutrition, enteral feeding formulas are essential. People who have long-term illnesses, neurological diseases, gastrointestinal issues, or cancer may have malnutrition. Enteral feeding formulae provide enough nourishment to avoid malnutrition-related problems such as muscular atrophy, weight loss, and vitamin shortages. Enteral feeding formulas assist keep the digestive system functioning properly by being delivered straight into the gastrointestinal tract. Patients with weak gastrointestinal function or restricted oral intake may benefit from this stimulation. It keeps the intestines healthy, promotes nutrition absorption, and guards against gastrointestinal issues. Enteral feeding formulae offer a way for those who are unable to eat or have trouble swallowing to get enough food and fluids.

This lessens discomfort, stops hunger, and boosts energy levels, all of which contribute to an overall improvement in their quality of life. Enteral feeding formulae enable patients to get nutrition assistance while continuing their everyday activities and routines in a variety of settings, such as hospitals, long-term care institutions, and home-based care. Because enteral feeding formulas come in a variety of formulations, medical experts can choose the one that best suits the needs of each patient. For those with certain medical illnesses, such as diabetes, renal failure, or liver disease, specialized formulae are available to ensure that their nutritional needs are satisfied while taking into account their particular dietary limitations and therapeutic requirements. Overall, the main drivers propelling the growth of the enteral feeding formula market are the aging population, the rising incidence of chronic diseases, the development of medical technology, the expansion of home-based treatment, and the growing awareness of patients and healthcare professionals.

Enteral Feeding Formulas Market Segment Analysis

In 2023, the standard formula segment held the largest market share at 56.8% due to widespread adoption and cost-effectiveness. The growth of this segment is expected to accelerate due to easy availability of polymeric nutritional complete formulas and physician recommendations. The disease-specific formulas segment is expected to grow rapidly due to the rise in chronic disorders like diabetes, cancer, and cardiovascular diseases. Manufacturers are developing and launching these products to meet patient needs.

For patients suffering from dysphagia and malnutrition, especially those in the senior population, the intermittent feeding flow segment—which had a dominant market share of 89.0% in 2023—is very helpful. Products for intermittent tube feeding, including Fresubin 1800 Complete, are being introduced by companies like Fresenius Kabi. A compound annual growth rate (CAGR) of 6.9% is anticipated for the continuous feeding flow market, especially for critically sick patients suffering from diseases including cancer, severe burns, and respiratory failure.

With a 90.4% market share in 2023, the adult segment led the industry. Malnutrition, chronic illnesses, and food insecurity are all on the rise worldwide. Patients with nasogastric, gastrostomy, enterostomy, or defective gastrointestinal tracts are fed enteral feeding formulae. 15% to 20% of all babies are low birth weight, and enteral feeding is also necessary for pediatric patients with gastrointestinal disorders. Because diseases including COPD, respiratory problems, cystic fibrosis, and infections are becoming more common, the market for enteral feeding formulas is anticipated to expand dramatically. 15% to 20% of babies born worldwide are underweight, and children with gastrointestinal disorders depend on enteral feeding to get nourished.

With 51.6% of revenue in 2023, the institutional sales segment led the market. Enteral nutrition products are purchased by healthcare facilities, such as hospitals and long-term care facilities. Growth is being driven by the population of people with chronic diseases and the expanding number of healthcare facilities. The fastest CAGR is anticipated for online sales. The home care segment is projected to grow at a CAGR of 5.8% over the forecast period, with various subtypes including hospices, nursing homes, adult day care centers, and residential care communities. The rising demand for enteral feeding formulas in hospitals is a significant indicator of this growth.

Enteral Feeding Formulas Market Key Players

• Abbott

• Braun Melsungen Ag

• Danone S.A

• Fresenius Kabi

• Global Health Products Inc

• Kate Farms

• Mead Johnson & Company, LLC

• Medtrition Inc.

• Meiji Holdings

• Nestle

• Nutritional Medicinals

• Otsuka Holdings Co.

• Primus Pharmaceuticals, Inc.

• Reckitt Benckiser Group.

• Victus

Enteral Feeding Formulas Market Regional Analysis

As of 2023, North America has the greatest market share, with 29.1%. The prevalence of head and neck cancer in the United States is predicted to increase the uptake of these formulae. For example, the CDC reports that 47,813 new instances of pharyngeal cancer and oral cavities were recorded nationwide in 2019. Furthermore, it is projected that throughout the projection period, the use of enteral feeding formulae would rise due to the rising prevalence of certain chronic illnesses, including neurological conditions.

Recent Developments:

• To combat the lack of supply in the institutional sector, Abbott said in September 2023 that it will increase production of a variety of adult enteral formulations for the retail market.

• Nestlé and EraCal Therapeutics began working together on a study in February 2023 to find new nutraceuticals for regulating food consumption.

• Kate Farms debuted Adult Standard 1.4 in September 2022; it is a high-calorie medicinal formula that is currently available in chocolate. This product features a delightful taste and is intended to help with weight gain, weight management, and increased tolerance.

Enteral Feeding Formulas Market Trends

Enteral meals are necessary for nutritional control of sarcopenia, an age-related disease that impairs muscular strength and function. Malnutrition and sarcopenia overlap, and sarcopenia is 1-29% common in elderly persons. Sarcopenia can be prevented and treated by enteral nutrition. The market for enteral feeding formulae is expanding as a result of the rise in preterm births and nutritional deficits, especially in newborns and pregnant women. Market expansion may be impeded by the incorrect classification of therapeutic nutrition, which is frequently confused with functional or nutritional foods. While regulatory authorities define clinical nutrition in the U.S. and Europe, rules are currently being developed in other regions of the world. Potential research and commercial expansion are impeded by the absence of a clear legal categorization.

Key Market Segments: Enteral Feeding Formulas Market

• By Product (Revenue, USD Billion, 2024 - 2033)

  • Standard Formula

  • Disease-specific Formulas

• Alzheimer’s

• Nutrition Deficiency

• Cancer Care

• Diabetes

• Chronic Kidney Diseases

• Orphan Diseases

• Dysphagia

• Pain Management

• Malabsorption/GI Disorder/Diarrhea

• Others

• By Flow Type (Revenue, USD Billion, 2024 - 2033)

  • Intermittent Feeding Flow

  • Continuous Feeding Flow

• By Stage (Revenue, USD Billion, 2024 - 2033)

  • Adults 

  • Pediatrics

• By Indication (Revenue, USD Billion, 2024 - 2033)

  • Alzheimer’s

  • Nutrition Deficiency

  • Cancer Care

  • Diabetes

  • Chronic Kidney Diseases

  • Orphan Diseases

  • Dysphagia

  • Pain Management

  • Malabsorption/GI Disorder/Diarrhea

  • Others

• By End-use (Revenue, USD Billion, 2024 - 2033)

  • Hospitals

    • Cardiology

    • Neurology

    • Critical Care (ICU)

    • Oncology

    • Others

  • Home Care

  • Long Term Care Facilities

• By Sales Channel (Revenue, USD Billion, 2024 - 2033)

  • Online Sales

  • Retail Sales

  • Institutional Sales

• By Region (Revenue, USD Billion, 2024 - 2033)

• North America

• Europe

• Asia Pacific

• Latin America

• MEA